MRUS logo

Merus N.V. Common Shares

MRUS

MRUS: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

more

Show MRUS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MRUS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MRUS's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Human cd3 binding antibody Aug. 29, 2023
  • Patent Title: Antibodies that modulate a biological activity expressed by a cell Aug. 22, 2023
  • Patent Title: Binding molecules that bind cd137 and pd-l1 Jun. 27, 2023
  • Patent Title: Binding molecules that modulate a biological activity expressed by a cell Jun. 06, 2023
  • Patent Title: Antibody producing non-human animals Jan. 24, 2023
  • Patent Title: Antibody producing non-human animals Sep. 20, 2022
  • Patent Title: Generation of binding molecules Aug. 09, 2022
  • Patent Title: Antibody that binds erbb-2 and erbb-3 Mar. 22, 2022
  • Patent Title: Antibody producing non-human animals Feb. 01, 2022
  • Patent Title: Antibody producing non-human mammals Apr. 06, 2021
  • Patent Title: Recombinant production of mixtures of antibodies Mar. 02, 2021
  • Patent Title: Antibodies that bind egfr and erbb3 Nov. 24, 2020
  • Patent Title: Methods and means for the production of ig-like molecules Aug. 25, 2020
  • Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Jun. 02, 2020
  • Patent Title: Generation of binding molecules May. 12, 2020
  • Patent Title: Recombinant production of mixtures of antibodies Dec. 17, 2019
  • Patent Title: Bispecific igg antibodies as t cell engagers Jul. 23, 2019
  • Patent Title: Methods and means for the production of ig-like molecules Jul. 02, 2019
  • Patent Title: Methods and means for the production of ig-like molecules Jun. 25, 2019
  • Patent Title: Human cd3 binding antibody Apr. 23, 2019
  • Patent Title: Antibody producing non-human mammals Apr. 24, 2018
  • Patent Title: Antibody producing non-human mammals Apr. 17, 2018
  • Patent Title: Human cd3 binding antibody Mar. 13, 2018
  • Patent Title: Generation of binding molecules Mar. 06, 2018
  • Patent Title: Antibody producing non-human mammals Sep. 19, 2017
  • Patent Title: Methods and means for the production of ig-like molecules Sep. 12, 2017
  • Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Aug. 22, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of MRUS in WallStreetBets Daily Discussion

MRUS News

Recent insights relating to MRUS

CNBC Recommendations

Recent picks made for MRUS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MRUS

Corporate Flights

Flights by private jets registered to MRUS